Brouse, S.D., J.C. Fullerton and M.Y. Moridani, 2010. Reporting and interpretation of CYP2C19 genotyping for clopidogrel dosing. Curr. Pharmac. Personalized Med., 8: 268-272.
CrossRef  |  

Galati, G., M.Y. Moridani, T.S. Chan and P.J. O'Brien, 2001. Peroxidative metabolism of apigenin and naringenin versus luteolin and quercetin: glutathione oxidation and conjugation. Free Radic. Biol. Med., 30: 370-382.
CrossRef  |  

Galati, G., S. Teng, M.Y. Moridani, T.S. Chan and P.J. O'Brien, 2000. Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics. Drug Metab. Drug Interact., 17: 311-349.
PubMed  |  Direct Link  |  

Harirforoosh, S., L. Fleckenstein, P. Mahajan, O.I. Aruoma, Y. Huang and M. Moridani, 2009. The importance of including topics related to pharmacogenetics, pharmacogenomics and medical genetics in the pharmacy curriculum. Am. J. Pharmac. Educ., 73: 2-3.
Direct Link  |  

Kudugunti, S.K., N.M. Vad, A.J. Whiteside, B.U. Naik, M.A. Yusuf, K.S. Srivenugopal adn M.Y. Moridani, 2010. Biochemical mechanism of Caffeic Acid Phenylethyl Ester (CAPE) selective toxicity towards melanoma cell lines. Chem. Biol. Interact., 188: 1-14.
CrossRef  |  

Moridani, M., 2004. A SNPpet of background on pharmacogenomics, College of American Pathologists. CAP Today, 18: 60-63.

Moridani, M., 2004. Pharmacogenomics of Phase I and Phase II drug metabolizing enzymes. CSCC News Lett., 46: 1-3.

Moridani, M., 2005. The significance of pharmacogenomics in pharmacy education and practice. J. Am. Pharmac. Educ., 69: 249-250.

Moridani, M., 2007. Asynchronous video streaming vs. Synchronous videoconferencing for teaching a pharmacogenetic pharmacotherapy course. J. Am. Pharmac. Educ., 71: 1-10.

Moridani, M., 2009. Pharmacogenomics testing: Required: Recommended or for information only. PGx Highlights, 1: 6-7.
Direct Link  |  

Moridani, M., 2009. Response and toxicity variations to vaccines. PGx Highlights, 1: 5-7.

Moridani, M., 2009. Technological advances in genomics research. PGx Highlights, 1: 7-9.

Moridani, M., 2010. CYP2C19 genotyping for clopidogrel dosing. CAP Today, 24: 14-16.

Moridani, M., 2010. Pharmacogenetics of the Renin-Angiotensin-Aldosterone system. PGx Highlights, 2: 6-8.

Moridani, M., 2011. The role of P450 genetic variations in drug and prodrug design. PGx Highlights, 3: 11-16.

Moridani, M.Y., A.H. Maitland-van der Zee, H. Sasaki, R. McKinnon, L. Fleckenstein and Vinod P. Shah, 2009. AAPS-FIP summary workshop report: Pharmacogenetics in individualized medicine: Methods, regulatory and clinical applications. AAPS J., 11: 214-216.
CrossRef  |  

Moridani, M.Y., S. Khan, T. Chan, S. Teng, K. Beard and P.J. O`Brien, 2001. Cytochrome P450 2E1 metabolically activates propargyl alcohol: Propiolaldehyde-induced hepatocyte cytotoxicity. Chem. Biol. Interact., 130-132: 931-942.
CrossRef  |  

Thomas, C. and M.Y. Moridani, 2010. Interindividual variations in the efficacy and toxicity of vaccines. Toxicology, 278: 204-210.
CrossRef  |  

Vad, N.M., G. Yount and M.Y. Moridani, 2008. Biochemical mechanism of acetylsalicylic acid (Aspirin) selective toxicity toward melanoma cell lines. Melanoma Res., 18: 386-399.
CrossRef  |  

Vad, N.M., G. Yount, D. Moore, J. Weidanz and M.Y. Moridani, 2009. Biochemical mechanism of acetaminophen (APAP) induced toxicity in melanoma cell lines. J. Pharm. Sci., 98: 1409-1425.
CrossRef  |  

Vad, N.M., P.K. Kandala, S.K. Srivastava and M.Y. Moridani, 2010. Structure-toxicity relationship of phenolic analogs as anti-melanoma agents: An enzyme directed prodrug approach. Chem. Biol. Interact., 183: 462-471.
Direct Link  |  

Vad, N.M., S.K. Kudugunti, D. Graber, N. Bailey, K. Srivenugopal and M.Y. Moridani, 2009. Efficacy of acetaminophen in skin B16-F0 melanoma tumor bearing C57BL/6 mice. Int. J. Oncol., 35: 193-204.
CrossRef  |